Drug
X-82 clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 1
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
- X-82
- 5
Studies by the year they started
6 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
Tyrogenex (3) · University of Wisconsin, Madison (1) · Washington University School of Medicine (1) · AnewPharma (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses X-82 is read from its arms, and is right about nine times in ten.
Testing it · 6
- Safety Study of X-82 in Patients With Advanced Solid TumorsCompletedPhase 1TyrogenexNCT01296581Written as X-82
- X-82 to Treat Age-related Macular DegenerationTerminatedPhase 2TyrogenexNCT02348359Written as X-82
- VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine TumorsTerminatedPhase 1/2Washington University School of MedicineNCT01784861Written as X-82
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownPhase 3AnewPharmaNCT03095040Written as CM082 combined with everolimus
- VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid TumorsCompletedPhase 1University of Wisconsin, MadisonNCT02146222Written as VEGFR/PDGFR dual kinase inhibitor X-82
- Pilot Study of X-82 in Patients With Wet AMDCompletedPhase 1/2TyrogenexNCT01674569Written as X-82 oral